Skip to content

Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence.

Ming-Chyi Huang, Lian-Yu Chen, Hu-Ming Chang, Xiao-Yu Liang, Chih-Ken Chen, Wan-Ju Cheng, Ke Xu

Frontiers in Psychiatry 2018 DOI: 10.3389/fpsyt.2018.00633 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational case-control study Peer reviewed
Sample size 130
Population 65 ketamine-dependent patients and 65 controls
Duration Baseline assessment and 1- and 2-week follow-up after ketamine withdrawal
Measures Beck Depression Inventory, Beck Anxiety Inventory (BAI), Visual Analog Scale for craving, Childhood Trauma Questionnaire-short form
Topics Addiction Ketamine Esketamine
Keywords Nmda antagonist Oxytocin Withdrawal
Key findings Ketamine-dependent patients had lower baseline plasma oxytocin than controls (5.89 vs. 9.53 ng/mL), and levels rose only partially after one and two weeks of withdrawal, remaining below controls. The authors argue this suggests oxytocin system dysregulation following chronic ketamine abuse and a possible link between lower oxytocin and an anxious phenotype of dependence.

Abstract

Background: Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is a common drug of abuse worldwide. Existing evidence suggest a disruption of oxytocin system involves in the development of addiction. In this study, we aimed to investigate the role of oxytocin in ketamine addiction by measuring the blood oxytocin levels in ketamine-dependent (KD) patients.

Methods: Sixty-five KD patients and 65 controls were enrolled. Fasting plasma levels of oxytocin were determined at baseline and 1 and 2 weeks after ketamine withdrawal. Ketamine use variables, Beck Depression Inventory, Beck Anxiety Inventory (BAI), Visual Analog Scale for craving, and Childhood Trauma Questionnaire-short form were assessed in KD patients.

Results: KD patients had significantly lower levels of oxytocin at baseline compared to controls (5.89 ± 2.13 vs. 9.53 ± 4.17 ng/mL, P < 0.001). Oxytocin levels increased after one (6.74 ± 2.63, P < 0.002) and 2 weeks (6.89 ± 2.69, P = 0.01) of withdrawal in KD patient despite the levels were still lower than controls (P = 0.001 and 0.002, respectively). The clinical variables did not correlate with baseline oxytocin levels except BAI scores, which showed a negative correlation with the levels (r = -0.263; P = 0.039).

Conclusion: We found a distinctively reduced oxytocin level in KD patients and the level did not normalize after early abstinence. Lower oxytocin might be associated with anxious phenotype of ketamine dependence. These results suggest that oxytocin system dysregulated following chronic ketamine abuse and might provide insight in evaluating the potential therapeutic use of oxytocin for treating ketamine dependence.

Comparable studies

Other observational and cohort studies on ketamine for addiction, most cited first.

Study Year Design Participants
Brain damages in ketamine addicts as revealed by magnetic resonance imaging Ketamine addicts 2014 Observational cohort n = 21
Characterization of Oral Ketamine Use: A Retrospective Review. Hospitalized patients aged 18 years or older receiving oral ketamine 2025 Retrospective cohort study
Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice. Patients receiving intramuscular ketamine with contemporaneous psychotherapy for... 2024 Observational study n = 70
Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance. Adults aged 18 years or older with major depressive disorder in the TriNetX US... 2026 Retrospective cohort study n = 30,670
Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy Adult chronic pain patients with comorbid substance misuse 2026 Observational study n = 20

Citations in the library

Explore topics

By condition and practice